胰高血糖素样肽-1受体激动剂与MASLD合并2型糖尿病患者的肝脏结局
本研究基于TriNetX多国多机构数据库,纳入2010年1月至2023年6月首次处方GLP-1 RA或SGLT2i的MASLD合并T2D成人患者,经倾向评分匹配后比较15,176对患者。GLP-1 RA组主要不良肝脏结局风险低于SGLT2i组(校正HR 0.84,95%CI 0.73-0.97),全因死亡率亦较低(校正HR 0.84,95%CI 0.75-0.94)。
要点
- GLP-1 RA较SGLT2i降低MASLD合并T2D患者主要不良肝脏结局风险(校正HR 0.84)。
- 获益主要由失代偿期肝硬化事件减少驱动(校正HR 0.83,95%CI 0.71-0.96)。
- GLP-1 RA组全因死亡率低于SGLT2i组(校正HR 0.84,95%CI 0.75-0.94)。
核心结论
- 在MASLD合并T2D患者中,GLP-1 RA与较SGLT2i更好的长期肝脏结局相关。
研究设计与样本
- 基于TriNetX Research Network多国多机构数据库的倾向评分匹配队列研究。
- 纳入2010年1月至2023年6月首次处方GLP-1 RA或SGLT2i的MASLD合并T2D成人患者。
- 倾向评分匹配后纳入15,176对患者。
主要发现
- GLP-1 RA相对SGLT2i的主要不良肝脏结局校正HR为0.84(95%CI 0.73-0.97;发生率88.9 vs 105.3/10,000人年)。
- 失代偿期肝硬化事件校正HR为0.83(95%CI 0.71-0.96)。
- 全因死亡率校正HR为0.84(95%CI 0.75-0.94)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated long-term liver benefits in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). However, no direct comparison between these therapies has been conducted. This study aimed to compare major adverse liver outcomes (MALOs) between GLP-1 RAs and SGLT2is in patients with MASLD and T2D. METHODS: Using the TriNetX Research Network, a multinational and multi-institutional database, we identified adults with MASLD and T2D who received their first prescription for either a GLP-1 RA or an SGLT2i between January 2010 and June 2023. We conducted a propensity score-matched (PSM) cohort study comparing new users of GLP-1 RAs and SGLT2is. The primary outcome was the risk of MALOs, a composite endpoint consisting of decompensated cirrhosis events, hepatocellular carcinoma, and liver transplantation. Secondary outcomes included all-cause mortality and individual components of the primary outcome. RESULTS: This study included 15,176 pairs of patients treated with either a GLP-1 RA or a SGLT2i. The adjusted hazard ratio (HR) for MALO associated with GLP-1 RAs relative to SGLT2is was 0.84 (95% confidence interval [CI]: 0.73-0.97; incidence rate: 88.9 versus 105.3 events per 10,000 person-years), primarily driven by reduction in decompensated cirrhosis events (adjusted HR: 0.83, 95% CI: 0.71-0.96). GLP-1 RAs were associated with lower all-cause mortality (adjusted HR: 0.84, 95% CI: 0.75-0.94). CONCLUSION: GLP-1 RAs are associated with better long-term liver outcomes compared to SGLT2is in patients with MASLD and T2D.
引用
- Kuo CC, Chuang MH, Li CH, et al. Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes. Aliment Pharmacol Ther. 2025. PMID: 39791391. doi:10.1111/apt.18502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。